• Je něco špatně v tomto záznamu ?

Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration

J. Radej, A. Krouzecky, P. Stehlik, R. Sykora, J. Chvojka, T. Karvunidis, I. Novak, M. Matejovic,

. 2011 ; 33 (4) : 393-7.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022588

INTRODUCTION: Voriconazole represents an essential part of antimicrobial therapy in critically ill patients. The aim of this study was to exclude a significant alteration in voriconazole pharmacokinetics in critically ill patients undergoing continuous venovenous hemofiltration (CVVH). METHODS: Six patients dependent on CVVH with evidence of an invasive mycotic infection treated with intravenous voriconazole at the standard dosing regimen were investigated. The total serum concentration of voriconazole in arterial blood and the concentration in ultrafiltrate were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection. The authors profiled a 5-point pharmacokinetic concentration-time curve during the 12-hour standard maintenance dosing interval and derived the basic pharmacokinetic parameters. RESULTS: The serum voriconazole concentration did not decrease <1.0 mg/L at any time point, and the mean was 4.3 ± 2.6 mg/L and the median (range) 3.6 (9.0) mg/L. The sieving coefficient of the drug did not exceed 0.30 in any patient (0.22 ± 0.08). The mean serum AUC0-12, the mean total clearance, and the mean clearance via CVVH were 53.52 ± 29.97 mg·h/L [the median (range) of 57.74 (62.34) mg·h/L], 0.11 ± 0.07 L·h-1·kg-1, and 0.007 ± 0.003 L·h-1·kg-1, respectively. The clearance by the CVVH method ranged from 4% to 20% of the total drug clearance. The disposition of voriconazole was not compromised. The mean elimination half-life was 27.58 ± 35.82 hours [the median of 13.10 (92.21) hours], and the mean distribution volume value was 3.28 ± 3.10 L/kg [the median of 2.01 (8.10) L/kg]. Marked variability in serum concentrations, elimination half-life, distribution volume, and total clearance was seen. Half of the patients showed some drug accumulation. CONCLUSIONS: The clearance of voriconazole by CVVH is not clinically significant. In view of this finding, voriconazole dose adjustment in patients undergoing the standard method of CVVH is not required. However, the observed potential for an unpredictable voriconazole accumulation suggests the usefulness for monitoring its levels in critically ill patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022588
003      
CZ-PrNML
005      
20121025092318.0
007      
ta
008      
120806s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1097/ftd.0b013e3182205d93 $2 doi
035    __
$a (PubMed)21654349
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Radej, Jaroslav $u 1st Medical Department, ICU, Charles University Medical School and Teaching Hospital, Plzen, Czech Republic. radejj@fnplzen.cz
245    10
$a Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration / $c J. Radej, A. Krouzecky, P. Stehlik, R. Sykora, J. Chvojka, T. Karvunidis, I. Novak, M. Matejovic,
520    9_
$a INTRODUCTION: Voriconazole represents an essential part of antimicrobial therapy in critically ill patients. The aim of this study was to exclude a significant alteration in voriconazole pharmacokinetics in critically ill patients undergoing continuous venovenous hemofiltration (CVVH). METHODS: Six patients dependent on CVVH with evidence of an invasive mycotic infection treated with intravenous voriconazole at the standard dosing regimen were investigated. The total serum concentration of voriconazole in arterial blood and the concentration in ultrafiltrate were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection. The authors profiled a 5-point pharmacokinetic concentration-time curve during the 12-hour standard maintenance dosing interval and derived the basic pharmacokinetic parameters. RESULTS: The serum voriconazole concentration did not decrease <1.0 mg/L at any time point, and the mean was 4.3 ± 2.6 mg/L and the median (range) 3.6 (9.0) mg/L. The sieving coefficient of the drug did not exceed 0.30 in any patient (0.22 ± 0.08). The mean serum AUC0-12, the mean total clearance, and the mean clearance via CVVH were 53.52 ± 29.97 mg·h/L [the median (range) of 57.74 (62.34) mg·h/L], 0.11 ± 0.07 L·h-1·kg-1, and 0.007 ± 0.003 L·h-1·kg-1, respectively. The clearance by the CVVH method ranged from 4% to 20% of the total drug clearance. The disposition of voriconazole was not compromised. The mean elimination half-life was 27.58 ± 35.82 hours [the median of 13.10 (92.21) hours], and the mean distribution volume value was 3.28 ± 3.10 L/kg [the median of 2.01 (8.10) L/kg]. Marked variability in serum concentrations, elimination half-life, distribution volume, and total clearance was seen. Half of the patients showed some drug accumulation. CONCLUSIONS: The clearance of voriconazole by CVVH is not clinically significant. In view of this finding, voriconazole dose adjustment in patients undergoing the standard method of CVVH is not required. However, the observed potential for an unpredictable voriconazole accumulation suggests the usefulness for monitoring its levels in critically ill patients.
650    _2
$a antiinfekční látky $x aplikace a dávkování $x krev $x farmakokinetika $7 D000890
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a kritický stav $7 D016638
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a poločas $7 D006207
650    _2
$a hemofiltrace $7 D006440
650    _2
$a lidé $7 D006801
650    _2
$a mykózy $x krev $x farmakoterapie $x metabolismus $7 D009181
650    _2
$a pyrimidiny $x aplikace a dávkování $x krev $x farmakokinetika $7 D011743
650    _2
$a triazoly $x aplikace a dávkování $x krev $x farmakokinetika $7 D014230
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krouzecky, Ales
700    1_
$a Stehlik, Pavel
700    1_
$a Sykora, Roman
700    1_
$a Chvojka, Jiri
700    1_
$a Karvunidis, Thomas
700    1_
$a Novak, Ivan
700    1_
$a Matejovic, Martin
773    0_
$w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 33, č. 4 (2011), s. 393-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21654349 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120806 $b ABA008
991    __
$a 20121025092523 $b ABA008
999    __
$a ok $b bmc $g 944501 $s 779885
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 33 $c 4 $d 393-7 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
LZP    __
$a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...